Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMedical University of Lublin

About this trial

The goal of this observational study is to learn whether high abdominal pressure or low blood flow pressure to the kidneys is linked to kidney injury after heart surgery. The main questions it aims to answer are:

Does high abdominal pressure increase the risk of kidney injury after cardiac surgery?

Can low blood flow pressure to the kidneys help predict who may develop kidney problems?

Participants in this study are adults undergoing heart surgery, such as coronary artery bypass grafting (CABG) or valve surgery. Researchers will measure abdominal pressure and blood pressure continuously before and after surgery using medical devices that are already part of routine care. This study does not involve any changes to standard treatment.

Participants will:

Have their abdominal and blood pressures continuously monitored using existing devices

Have blood and urine tests to check kidney function

Be followed during their hospital stay and up to 30 days after surgery to assess outcomes like length of stay, readmission, and survival

This study takes place at two hospitals-one in Poland and one in the United States. Researchers hope the findings will help identify early warning signs of kidney injury and improve monitoring practices after heart surgery.

Eligibility criteria

Qualifiers

Age 18 years or older

Undergoing cardiac surgery (CABG, valve surgery, combined procedures, heart transplantation, or placement of assist device)

Expected hospital stay of at least one night

Preoperative serum creatinine measurement available

Disqualifiers

Age below 18 years

Incarcerated individuals

No requirement for urinary catheter placement

Presence of a do-not-resuscitate (DNR) order

Trial design

Treatments tested in this trial

  • Continous IAP measurement

Treatment groups

45 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Medical University of Lublin

Lead sponsor

Wake Forest University Health Sciences

Collaborator